Treatment of other coagulation factor deficiencies
| Deficiency . | Treatment* . |
|---|---|
| Factor VII deficiency | |
| 20%-50%—mild | |
| 10%-20%—moderate; at risk for mild or provoked bleeding | |
| <10%—severe | Low-dose rFVIIa or plasma |
| Factor XI deficiency | |
| 20%-60%—variable risk for bleeding | |
| <20%—still variable risk for bleeding | Plasma or FXI concentrate where available |
| Fibrinogen deficiency | |
| <60mg/dL—at risk for miscarriage | Fibrinogen concentrates where available are the treatment of choice for patients with quantitative or qualitative deficiencies; otherwise, cryoprecipitate for antepartum as well as peripartum prophylaxis. |
| <100mg/dL—at risk for placental abruption | |
| <150mg/dL—at risk for placental abruption in labor and PPH | |
| Factor XIII deficiency | |
| <10%—severe; high risk for miscarriage and PPH | FXIII concentrate where available for antepartum as well as peripartum prophylaxis |
| Deficiency . | Treatment* . |
|---|---|
| Factor VII deficiency | |
| 20%-50%—mild | |
| 10%-20%—moderate; at risk for mild or provoked bleeding | |
| <10%—severe | Low-dose rFVIIa or plasma |
| Factor XI deficiency | |
| 20%-60%—variable risk for bleeding | |
| <20%—still variable risk for bleeding | Plasma or FXI concentrate where available |
| Fibrinogen deficiency | |
| <60mg/dL—at risk for miscarriage | Fibrinogen concentrates where available are the treatment of choice for patients with quantitative or qualitative deficiencies; otherwise, cryoprecipitate for antepartum as well as peripartum prophylaxis. |
| <100mg/dL—at risk for placental abruption | |
| <150mg/dL—at risk for placental abruption in labor and PPH | |
| Factor XIII deficiency | |
| <10%—severe; high risk for miscarriage and PPH | FXIII concentrate where available for antepartum as well as peripartum prophylaxis |
Includes the general guidance described under “Management of pregnant women with any bleeding disorder.”